Understanding immune responses to improve vaccine effectiveness against Staphylococcus aureus infections
Protective versus deleterious immune responses that impact vaccine efficacy against Staphylococcus aureus bloodstream infection
['FUNDING_R01'] · ABVACC, INC. · NIH-10832585
This study is looking at how our immune system fights off a bacteria called Staphylococcus aureus, which can cause serious infections, to help improve vaccines and treatments for people who might get these infections.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ABVACC, INC. (nih funded) |
| Locations | 1 site (ROCKVILLE, UNITED STATES) |
| Trial ID | NIH-10832585 on ClinicalTrials.gov |
What this research studies
This research investigates how the immune system responds to Staphylococcus aureus, a bacteria that can cause severe bloodstream infections. It aims to identify the immune mechanisms that can either protect against or worsen these infections, particularly in the context of vaccine development. The study will analyze immune responses in patients to determine why previous vaccine attempts have failed and how to improve future vaccine efficacy. By focusing on the immune responses that lead to better outcomes, the research seeks to develop effective host-directed therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals at high risk for Staphylococcus aureus infections, such as those undergoing cardiothoracic surgery or with compromised immune systems.
Not a fit: Patients who are not at risk for Staphylococcus aureus infections or those who have already been vaccinated against it may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of a safe and effective vaccine against Staphylococcus aureus bloodstream infections, significantly reducing morbidity and mortality.
How similar studies have performed: While there have been challenges in developing effective vaccines against Staphylococcus aureus, understanding immune responses has shown promise in other infectious disease research, indicating potential for success in this area.
Where this research is happening
ROCKVILLE, UNITED STATES
- ABVACC, INC. — ROCKVILLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: AMAN, M JAVAD — ABVACC, INC.
- Study coordinator: AMAN, M JAVAD
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome, Acquired Immunodeficiency Syndrome